NEW YORK (GenomeWeb) – Ashburn, Virginia-based Aperiomics today announced that it has closed a seed round of funding, raising $512,000, led by Pipeline Angels, a national network of new and seasoned women angel investors.
The firm said that by focusing on integrative health providers and private practice physicians, it has grown its customer base more than tenfold during 2017.
Aperiomics said that in a single test, it can identify every known pathogen, including bacteria, viruses, fungi, or parasites. Clinicians and patients call on the company to aid in the identification of infectious diseases that other tests cannot identify or would require a multitude of tests and an idea of what to look for, the firm added.
Through next-generation sequencing of the DNA or RNA in a sample, a complete genetic fingerprint is created and run through a proprietary data analysis algorithm to profile the sample.
Chemical Angel Network also participated in the round.
Aperiomics noted that the National Science Foundation has also been a strong supporter and has provided $1.6 million in grants to the company to date. An additional NSF research grant is expected and will, in part, fund efforts to improve the cost efficiency of the Aperiomics DNA sequencing process, the firm said.